Acuta Capital Partners, LLC Alkermes Plc. Transaction History

Acuta Capital Partners, LLC

  • $98.8 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$27.17 - $31.97 $2.22 Million - $2.62 Million
81,811 Added 183.07%
126,500 $3.54 Million
Q2 2023

Aug 14, 2023
BUY
$28.34 - $33.63 $368,420 - $437,190
13,000 Added 41.02%
44,689 $1.4 Million
Q1 2023

May 15, 2023
BUY
$25.31 - $29.02 $802,048 - $919,614
31,689 New
31,689 $893,000

Others Institutions Holding ALKS

# of Institutions
358
Shares Held
180M
Call Options Held
175K
Put Options Held
96.6K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $5.12B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email